Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. CEPH, and Eurand, Inc., for a Temporary Restraining Order enjoining Mylan Pharmaceuticals Inc., and Mylan Inc. MYL, from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX®.
The TRO remains in effect pending appeal.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in